Overall market sentiment has been neutral on Verastem Inc (VSTM) stock lately. VSTM receives a Neutral rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With VSTM Stock Today?
Verastem Inc (VSTM) stock has gained 3.3% while the S&P 500 is down -0.03% as of 3:20 PM on Thursday, Jun 18. VSTM is higher by $0.06 from the previous closing price of $1.74 on volume of 4,274,491 shares. Over the past year the S&P 500 has risen 6.68% while VSTM is down -1.10%. VSTM lost -$1.84 per share in the over the last 12 months.
To screen for more stocks like Verastem Inc click here.
More About Verastem Inc
Verastem Inc is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.
